Kerala-based life sciences company PNB Vesper announced that it has successfully completed the COVID-19 Phase 2 Clinical Trials and submitted the final report of its proprietary drug PNB-001 (GPP-Baladol) to the Drug Controller General of India (DCGI). GPP-Baladol is a novel and safe medicine that possesses significant efficacy to save the COVID-19 hospitalised patients with oxygen support, from the deadly coronavirus. PNB Vesper has approached the DCGI and the Government of India for an Emergency Use Authorisation of the drug for COVID-19 hospitalised patients.
